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Background
Chronic obstructive pulmonary disease (COPD) is a highly 
prevalent heterogeneous disease characterized by progressive 
airflow obstruction, chronic bronchitis, and emphysema. The 
predominant cause of COPD is tobacco smoking, but other 
exposures including air pollution and indoor exposures to bio-
mass fuels may be contributory in some. Prominent symptoms 
include cough, sputum, and dyspnoea.1 Patients are also at risk 
of acute exacerbations which are associated with increased 
health care utilization, morbidity, and death, whereas multiple 
factors can predict the risk for these events.2
The clinical manifestations and pathophysiologic abnor-
malities of COPD can vary greatly between patients.3 
Consequently, the prognosis is highly variable, ranging from 
stable disease with little functional impact, to severe, 
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ABSTRACT
RATIOnALe: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and development of novel therapeutics requires 
an understanding of pathophysiologic phenotypes.
OBjeCTIveS: The purpose of the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study was to correlate clinical fea-
tures and biomarkers with molecular characteristics in a well-profiled COPD cohort.
MeThODS: A total of 67 COPD subjects (forced expiratory volume in the first second of expiration [FEV1]: 45%-80% predicted) and 63 
healthy smoking and nonsmoking controls underwent multiple assessments including patient questionnaires, lung function, and clinical bio-
markers including fractional exhaled nitric oxide (FENO), induced sputum, and blood.
MeASuReMenTS AnD MAIn ReSuLTS: The impact of inhaled corticosteroids (ICSs), and to a lesser extent current smoking, was more 
associated with symptom control, exacerbation rates, and clinical biomarkers, than severity by FEV1. The ICS-treated smoking subjects were 
most symptomatic, with significantly elevated scores on patient-reported outcomes and more annual exacerbations (P < .05). Inhaled corti-
costeroid users had greater airflow obstruction and air trapping compared with non-ICS users, regardless of smoking status. Smoking, 
regardless of ICS use, was associated with significantly lower FENO (P < .05). Smoking, in non-ICS users, was associated with an elevated 
proportion of sputum neutrophils and reduced sputum macrophages. Increased serum C-reactive protein was observed in smokers but not 
in ICS and nonsmoking ICS users (P < .05). In contrast, only air trapping and neutrophilic inflammation increased with severity, defined by 
postbronchodilator FEV1.
COnCLuSIOnS: Compared with COPD severity by FEV1, ICS use and current smoking were better determinants of clinical characteristics 
and biomarkers. Use of the ADEPT COPD data promises to prove useful in defining biological phenotypes to facilitate personalized thera-
peutic approaches.
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progressive, and ultimately fatal disease. There is a need for 
better understanding of the specific disease mechanisms that 
drive COPD heterogeneity and to better understand how to 
match therapies to phenotypes.4 On a deeper level, linking 
phenotypes to specific pathogenic mechanisms, ie, endotypes, 
may allow more targeted approaches as recently reviewed.5
The primary objective of the Airways Disease Endotyping 
for Personalized Therapeutics (ADEPT) study was to assess 
molecular and cellular profiles in multiple matrices including 
induced sputum (IS), bronchial tissue, and blood, to enable the 
correlation of molecular subtyping with clinical characteristics 
first in asthma,6 followed by COPD.
Other programs have extensively characterized COPD. The 
ECLIPSE (Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate End-points) study was a 3-year longitudi-
nal study that evaluated pulmonary function, chest computed 
tomography (CT), biomarker measurement, health outcomes, 
body impedance, resting oxygen saturation, and 6-minute walk-
ing distance.7 Unlike ADEPT, this study did not obtain bron-
chial tissue but included CT imaging and followed phenotypes 
over 3 years. SPIROMICS (Subpopulations and Intermediate 
Outcomes in COPD Study) aims to enroll 3200 subjects in 4 
strata, with the principal objective being to identify phenotypes 
to guide personalized therapy.8 SPIROMICS includes imaging, 
biomarker assessments, substudies with bronchoscopy sampling, 
exacerbation evaluation, and multiyear follow-up. COPDGene 
(COPD gene study) is a 10 000-patient study evaluating smok-
ers and COPD patients using imaging, and genetic characteriza-
tion with genome-wide association studies, and includes 
long-term follow-up to quantify disease progression.9
This report focuses on the differential impact of disease 
severity measured by lung function, current smoking status, 
and inhaled corticosteroid (ICS) use on subject characteristics 
and biomarkers.
Methods
Design
The ADEPT COPD study was a cross-sectional, observa-
tional noninterventional study of patients with COPD and 
healthy subjects run in North America, Germany, United 
Kingdom, Romania, and Denmark from 2012 to 2014. The 
study received institutional ethics approval at all sites. All sub-
jects provided written informed consent (genomic testing was 
optional). The clinicaltrials.gov identifier is NCT01274507. 
The full study protocol is linked to this report.
Men and women, aged 40 to 65 years, produced a valid sam-
ple of IS at screening and were fit for bronchoscopy, with a 
body mass index (BMI) <32 kg/m2. Important inclusion and 
exclusion criteria are described below, and all criteria are in the 
protocol linked to this report.
Healthy subjects. Recruitment of 30 healthy nonsmokers and 
30 healthy asymptomatic smokers was planned, with no 
clinically significant abnormalities in medical history, vital 
signs, physical examination, routine laboratory analyses, and 
an electrocardiogram. Subjects with significant bronchodila-
tor reversibility (BDR) of ≥12% and ≥200 mL or a forced 
expiratory volume in the first second of expiration (FEV1) 
value <85% of predicted normal were excluded. Nonsmokers 
were required not to have smoked in the previous year and 
have a ≤10 pack-year history of smoking. A positive urinary 
cotinine was exclusionary. Smokers were required to be cur-
rently smoking with a history of ≥20 pack-years. Subjects who 
had respiratory symptoms or a FEV1/forced vital capacity 
ratio <0.7 were excluded.
COPD subjects. The COPD subjects were enrolled into 2 sever-
ity cells to ensure a range of severity. These were as follows: (1) 
“moderate COPD”-postbronchodilator (post-BD) FEV1 
between 60% and <80% predicted and (2) “severe COPD”-post-
BD FEV1 between 45% and <60% predicted (adapted from 
COPD guidelines1). All participants had stable COPD for 
3 months prior to screening, were active or previous smokers 
with ≥10 pack-year history, and were on ≥1 COPD medication 
in the 4 weeks prior to screening. Exclusion criteria included the 
following: a history of asthma, other chronic lung diseases, life-
threatening COPD exacerbations, right heart failure, a pulse oxi-
metry <90% on room air, and long-term oxygen therapy at rest.
Study Design and Visits 
All participants underwent screening visits, followed within 
~14 days by a baseline biomarker assessment visit, and then 
~14 days later, a bronchoscopy visit. The complete study proce-
dures and detailed methodology are in the protocol linked to 
this report. The study procedures were as follows:
1. Spirometry before and after a short-acting bronchodilator;
2. Postbronchodilator body plethysmography was per-
formed in COPD subjects only for residual volume 
(RV), total lung capacity (TLC), functional residual 
capacity (FRC);
3. Diffusing capacity of lung for carbon monoxide in 
COPD subjects only;
4. In COPD subjects, patient-reported outcomes (PROs): 
the St. George’s Respiratory Questionnaire for COPD 
(SGRQc)10 and a novel symptom score, the EXACT 
(EXAcerbations of Chronic Obstructive Pulmonary 
Disease Tool) respiratory symptoms scale (E-RS).11 The 
E-RS involves the use of 11 of the 14 EXACT12 items 
and a new scoring algorithm to assess the severity of 
respiratory symptoms in patients with COPD. A pur-
pose-built novel COPD history questionnaire (CHQ) 
was also administered;
5. Fractional exhaled nitric oxide (FENO), airway mucosal 
biopsy and brushings, IS, nasal brushings, whole blood, 
serum, urine, and genomic samples were also collected.
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Biomarker Assessments 
These are described in detail in the online supplement.
Safety
Investigators were instructed to capture adverse events (AEs) 
that were attributed to study procedures, eg, sputum induction 
and bronchoscopy. Emergent AEs that were unrelated to pro-
cedures were captured at the investigators’ discretion.
Statistical considerations
Based on a priori hypotheses that current smoking status and 
ICS use would be major extrinsic factors affecting both clini-
cal and molecular phenotypes, the primary analyses included 
comparisons among 4 COPD groups defined by smoking 
and ICS status and these groups to respective healthy control 
nonsmoker and currently smoking cohorts. The 4 COPD 
groups were as follows: (1) ICS-treated smoking (ICS/SM) 
(n = 26), (2) ICS-treated nonsmoking (ICS/NSM) (n = 15), 
(3) ICS-nontreated smoking (ICS-NO/SM) (n = 20), and 
(4) ICS-nontreated nonsmoking (ICS-NO/NSM) (n = 6). 
Active smoking was based on the medical records and/or a 
positive urinary cotinine at any study visit. Inhaled corticos-
teroid use was based on medications captured in the case 
report form.
Statistical analyses of clinical and biomarker data used 
OmicSoft Array Studio v8 (Cary, NC, USA). No imputation 
was performed for missing data. For data with lognormal dis-
tributions (eg, FENO, blood differential counts), logarithm 
transformations were performed. Significance of differences 
among groups, and interactions between groups, was evaluated 
using General Linear Model analyses. To test for significance 
of difference in proportions between categorical variables, 
Fisher exact tests were used. Correlations among variables were 
tested using Spearman correlation tests that do not require 
assumptions of normality and linearity. A P value of <.05 was 
considered to be statistically significant. In light of the explora-
tory hypothesis-generating nature of the study, no correction 
for multiple comparisons was performed.
Results
Study population
Healthy controls. In total, 63 healthy subjects (31 nonsmokers 
and 32 smokers) were enrolled. Of the 63 healthy subjects, 3 
(4.8%) subjects terminated study participation prematurely, 1 
due to withdrawal of consent, and 2 for “other” reasons. Healthy 
nonsmokers were slightly younger than the healthy smokers 
and both groups were significantly younger than COPD par-
ticipants (mean ± SD: 49 ± 7 vs 58 ± 5; P < 10−6). Healthy non-
smokers were predominantly women, but the smokers were 
approximately balanced for sex. Demographic characteristics 
are shown in Table 1.
Impact of smoking on lung function in healthy 
controls
Despite requirements for normal lung function, healthy con-
trol smokers had numerically worse values for all spirometric 
values compared with healthy nonsmokers, but only prebron-
chodilator (pre-BD) FEV1 %predicted was significantly 
lower (P = .015), although still in the normal range (Figure 1, 
panel A).
COPD subjects
Demographics and disposition for COPD subjects. A total of 67 
COPD subjects were enrolled; of whom 62 (92.5%) com-
pleted the study, whereas 5 (7.5%) subjects terminated the 
study participation prematurely. Most of the COPD subjects 
were men (60%) and white (91.0%). About 61% of COPD 
subjects were on ICS and 69% were current smokers. Within 
ex-smokers and current smokers, 71% and 57% were on ICS, 
respectively. A key finding from the purpose-built COPD 
questionnaire (CHQ) was a high burden of comorbid condi-
tions, with a high prevalence of gastroesophageal reflux dis-
ease and hypertension in COPD as previously reported.13 
About 68% of subjects continued to smoke, and the preva-
lence of continuing second-hand smoke exposure at home 
(50%) and at work (25%) was disturbingly high. About 26% 
reported ≥3 exacerbations per year, with a modest correlation 
of exacerbation rate FEV1, in agreement with previous reports 
that exacerbations rise with increasing severity, although they 
also occur in milder disease and even smokers with no airflow 
obstruction.14 Of note, despite asthma being an exclusion cri-
terion, 9% of severe COPD subjects self-reported a history of 
asthma before they developed COPD.
Subgrouping by smoking status and use of inhaled steroids. Divi-
sion of the COPD population into 4 groups based on use of 
ICS and smoking status (as described in the “Methods” sec-
tion) was found to be associated with significantly more COPD 
clinical characteristics and biomarkers than analysis by FEV1 
severity and is therefore the focus of this report. The 4 COPD 
groups were as follows: (1) ICS-treated smoking (ICS/SM) 
(n = 26), (2) ICS-treated nonsmoking (ICS/NSM) (n = 15), (3) 
ICS-nontreated smoking (ICS-NO/SM) (n = 20), and (4) 
ICS-nontreated nonsmoking (ICS-NO/NSM) (n = 6).
Demographic characteristics are shown in Table 1 for 
COPD subjects by ICS use and smoking. Demographic 
parameters did not differ within the 4 COPD groups, but the 
COPD subjects were significantly older than the healthy 
controls. Use of long-acting β2 agonists tracked with ICS in 
ICS users only.
There were no significant demographic factors associated 
with the 4 smoking/ICS groups that could potentially influ-
ence the observed differences in lung capacity measurements 
and PROs. Specifically, there were no significant differences in 
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age, sex, and race among the 4 groups. However, there was a 
nonsignificant trend for modestly lower BMI in active smok-
ers, as expected. Demographic variables also were not corre-
lated with % predicted post-BD FEV1 values, with only a 
nonsignificant trend higher age correlating with lower % pre-
dicted FEV1 measurements (r = −.21, P = .091; data not shown).
Impact of active smoking and/or ICS use on COPD 
clinical characteristics
Disease characteristics with significant smoking-ICS interac-
tions or between-group differences are presented in Table 2 for 
each of the 4 groups (ICS/SM, ICS/NSM, ICS-NO/SM, and 
ICS-NO/NSM). The F test relates to the significant impact of 
ICS use and/or active smoking. The full data sets are presented 
in supplemental Table E1 (spirometry, COPD PROs, and ple-
thysmography parameters) and Tables E2 and E3 (P values for 
between-group comparisons). In general, ICS use was associ-
ated with more differences for clinical than biomarker param-
eters, whereas smoking affected less parameters overall and 
more biomarkers than clinical parameters.
Use of ICS, regardless of smoking status (ICS/SM and 
ICS/NSM), had greater airflow obstruction in general based 
on spirometry compared with non-ICS users (ICS-NO/NSM 
and ICS-NO/SM) (Figure 1 and Table 2).
The ICS/SM group was the most symptomatic, with sig-
nificantly elevated EXACT scores compared with the other 3 
groups and SGRQc scores compared with ICS/NSM and 
ICS-NO/NSM groups (P < .05) (Figure 2 and supplemental 
Table E3). In addition, this group had a significantly greater 
annual exacerbation rate compared with the ICS-NO/SM and 
ICS-NO/NSM groups (P < .05), associated with ICS use.
The ICS-treated groups regardless of smoking status had sig-
nificantly greater FRC values compared with ICS-nontreated 
subjects. Similar patterns pertained to TLC, RV, and RV/TLC 
(Table 2, Figure 3, and supplemental Tables E1 and E3).
Impact of active smoking and/or ICS use on 
biomarkers
Supplemental Tables E4 and E5 present all the evaluated bio-
markers for the 4 COPD groups. Table 2 and Figure 4 present 
a subset of these biomarkers that differed by active smoking or 
ICS use. Inhaled corticosteroid use and smoking affected a 
similar number of biomarkers. There was suppression of FENO 
in smokers regardless of ICS use as previously reported.15 
Inhaled corticosteroid use was associated with an elevated 
absolute number of sputum neutrophils, a reduced absolute 
number of sputum macrophages, and increased serum 
C-reactive protein (CRP) levels particularly in the context of 
current nonsmoking status (P < .05).
Correlations of disease characteristics with FEV1 
severity
Postbronchodilator FEV1 % predicted was used as the indica-
tor of severity (see Table 3, reporting significant correlations 
and supplement Table E6 for the full variable list).
There were several correlations of spirometric parameters with 
post-BD FEV1 as expected and not called out here. Regarding 
post-BD plethysmography, RV/TLC (% predicted) moderately 
(r = −.43) and FRC (% predicted) modestly (r = −.29) were 
inversely correlated with post-BD FEV1. Diffusing capacity of 
lung for carbon monoxide (% predicted) was modestly inversely 
Figure 1. Airflow obstruction associated with smoking prebronchodilator in healthy controls but not COPD subjects: (A) prebronchodilator and (B) 
postbronchodilator FEV1 expressed as % predicted normal and (C) prebronchodilator and (D) postbronchodilator FEV1/FVC ratio, stratified by smoking 
and ICS use status, are presented as symbols representing individual participants and summarized by box (interquartile range and median) and whiskers 
(range), with “+” indicating the mean. †P < .05 for current (SM) vs ex-smokers (NSM) within indicated ICS status/disease group. COPD indicates chronic 
obstructive pulmonary disease; FEV1, forced expiratory volume in the first second of expiration; FVC, forced vital capacity; ICS, inhaled corticosteroid; 
ICS/NSM, ICS-treated nonsmoking; ICS/SM, ICS-treated smoking; ICS-NO/NSM, ICS-nontreated nonsmoking; ICS-NO/SM, ICS-nontreated smoking; 
NSM, nonsmoking; SM, smoking.
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Figure 2. Patient-reported outcomes worst in currently smoking COPD subjects on ICS. (A) EXACT scores, (B) SGRQ total score, and (C) exacerbation 
history of COPD, stratified by smoking and ICS use status, is presented as symbols representing individual participants and summarized by box (interquartile 
range and median) and whiskers (range), with “+” indicating the mean. *P < .05 for current (SM) vs ex-smokers (NSM) within indicated ICS status group; 
†P < .05 for ICS vs ICS-NO within indicated smoking status group. COPD indicates chronic obstructive pulmonary disease; EXACT, EXAcerbations of Chronic 
Obstructive Pulmonary Disease Tool; ICS, inhaled corticosteroid; ICS/NSM, ICS-treated nonsmoking; ICS/SM, ICS-treated smoking; ICS-NO/NSM, 
ICS-nontreated nonsmoking; ICS-NO/SM, ICS-nontreated smoking; NSM, nonsmoking; SGRQ, St. George’s Respiratory Questionnaire; SM, smoking.
8 Biomarker Insights 
Figure 3. Plethysmography measurements were worst in currently smoking COPD subjects on ICS. % predicted normal values for (A) total lung capacity 
(TLC), (B) functional residual capacity, (C) residual capacity, and (D) the ratio of residual volume over TLC, stratified by smoking and ICS use status, are 
presented as symbols representing individual participants and summarized by box (interquartile range and median) and whiskers (range), with “+” 
indicating the mean. †P < .05 for ICS vs ICS-NO within indicated smoking status/disease group. COPD indicates chronic obstructive pulmonary disease; 
ICS, inhaled corticosteroid; ICS/NSM, ICS-treated nonsmoking; ICS/SM, ICS-treated smoking; ICS-NO/NSM, ICS-nontreated nonsmoking; ICS-NO/SM, 
ICS-nontreated smoking.
Figure 4. Biomarkers in healthy controls and COPD subjects impacted by smoking and ICS. Density of blood (A) eosinophils and (B) neutrophils, (C) 
density and (D) proportion of leukocytes for sputum neutrophils, (E) serum C-reactive protein concentration, and (F) FENO, stratified by smoking and ICS 
use status, are presented as symbols representing individual participants and summarized by box (interquartile range and median) and whiskers (range), 
with “+” indicating the mean. *P < .05 for current (SM) vs ex-smokers (NSM) within indicated ICS status/disease group; †P < .05 for ICS vs ICS-NO within 
indicated smoking status/disease group. COPD indicates chronic obstructive pulmonary disease; FENO, fractional exhaled nitric oxide; ICS, inhaled 
corticosteroid; ICS/NSM, ICS-treated nonsmoking; ICS/SM, ICS-treated smoking; ICS-NO/NSM, ICS-nontreated nonsmoking; ICS-NO/SM, ICS-
nontreated smoking; NSM, nonsmoking; SM, smoking.
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Table 3. Correlations of clinical and biomarker variables with post-BD FEV1 (% predicted).
VARIABLEa,b UNADJUSTEDa ADJUSTEDa N
RSP P VALUE RSP P VALUE
Post-BD FEV1, % predicted 1.00 <10−6 1.00 <10−6 67
Pre-BD FEV1, % predicted 0.88 <10−6 0.89 <10−6 67
Post-BD FVC, % predicted 0.70 <10−6 0.69 <10−6 67
Pre-BD FVC, % predicted 0.68 <10−6 0.68 <10−6 67
Post-BD FEV1 (L) 0.61 <10−6 0.62 <10−6 67
Pre-BD FEV1 (L) 0.60 <10−6 0.61 <10−6 67
Post-BD RV/TLC, % predicted −0.43 .0004 −0.38 .0019 65
Pre-BD FVC, % predicted 0.39 .0011 0.42 .0004 67
Post-BD FVC, % predicted 0.38 .0017 0.40 .0009 67
spMAC % 0.37 .0102 0.34 .0189 47
Post-BD RV (L) −0.37 .0026 −0.34 .0059 65
spLyM % 0.34 .0214 0.28 .0565 47
bNEU (×10E9/L) −0.33 .0068 −0.34 .0053 66
spNEU % −0.33 .0252 −0.30 .0396 47
DLCO, % predicted 0.32 .0115 0.37 .0032 61
Post-BD FRC, % predicted −0.29 .0184 −0.22 .0830 65
Pre-BD FVC (L) 0.29 .0191 0.31 .0111 67
Post-BD RV, % predicted −0.26 .0366 −0.25 .0417 65
Post-BD FRC (L) −0.32 .0102 −0.21 .0987 65
Annual rate exacerbations (ChQ) −0.28 .0383 −0.18 .2035 54
Abbreviations: bNEU, blood neutrophils; CHQ, COPD history questionnaire; DLCO, diffusing capacity of lung for carbon monoxide; FEV1, forced expiratory volume at 1 
second; FRC, functional residual capacity; FVC, forced vital capacity; post-BD, postbronchodilator; spLyM, sputum lymphocytes; spMAC, sputum macrophages; spNEU, 
sputum neutrophils.
a Spearman correlation tests were performed for the indicated variables vs baseline post-BD FEV1 % predicted for the actual (unadjusted) values for all patients with 
COPD or after analysis of variance–based adjustment of the data set for smoking status and ICS use.
b Variables displayed are for those that had P < .05 for the nonadjusted data set; 2 variables in bold had P < .05 for the unadjusted but not adjusted data set.
correlated with post-BD FEV1 (r = .31). Annual exacerbation 
rates also increased with severity, with a modest inverse correla-
tion to post-BD FEV1 (r = −.26). Notably, post-BD FEV1 was 
not significantly correlated with BDR or disease activity ques-
tionnaires (SGRQ, EXACT scores), as shown in Supplemental 
Table E6.
Correlations of biomarkers with FEV1 severity
Blood neutrophil density and sputum neutrophil percentages 
were similarly inversely correlated with post-BD FEV1 
(r = −.33), increasing with severity, whereas sputum macrophage 
and lymphocyte percentages similarly decreased with severity 
(r = .34-.37). Postbronchodilator FEV1 was not significantly 
correlated with serum CRP. Sputum eosinophils were not cor-
related with severity, nor did they differ from healthy control 
groups, with both groups having 13% of participants with >3% 
sputum eosinophils (data not shown).
Because current smoking and ICS use could also directly 
affect these variables and confound the interpretation, all cor-
relations were also tested after adjusting the data set for smok-
ing status and ICS use. Despite this adjustment, all the above 
correlations with post-BD FEV1 held, except for the correla-
tion with annual exacerbation rate (which went from signifi-
cant, r = −.28, P = .038 to insignificant, r = −.18, P = .20), 
consistent with ICS reducing exacerbation rates.
Safety
There were no serious AEs related to the study procedures.
Discussion
The major finding in a well-characterized cohort of COPD is 
that active smoking and/or ICS use were of greater impact in 
driving differences in PROs, lung volumes, and biomarkers 
than severity by post-BD FEV1.
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Of note, the healthy control cohort was significantly younger 
than the COPD subjects, and age was a significant covariate in 
multiple biomarker analyses (data not shown). The healthy 
smokers had a significantly lower pre-BD FEV1 % predicted 
(albeit within the normal range) compared with healthy con-
trol nonsmokers and significantly elevated blood neutrophil 
density. The possibility remains that this cohort included sub-
jects with early COPD in keeping with Regan and colleagues,14 
who described acute exacerbations in smokers without COPD.
The CHQ provided a more comprehensive insight into 
COPD history than the SGRQ and E-RS. Even though this 
questionnaire was created for ADEPT and has not been for-
mally validated, important insights regarding the COPD dis-
ease experience were gained.
In contrast to severity defined by post-BD FEV1 (discussed 
below), active smoking and/or ICS therapy were confounding 
factors for comparisons between multiple clinical and bio-
marker parameters. The ICS/SM group was the most severe by 
EXACT and SGRQ scores, a greater annual exacerbation rate, 
worse airflow obstruction, and hyperinflation. In general, ICS 
negatively affected these parameters in the presence or absence 
of active smoking. It is not possible to establish cause and 
effect, but ICS use is probably a marker of greater severity 
driven by clinical practice guidelines, which recommend add-
ing ICS for those experiencing exacerbations, although ICS 
use is associated with increased risk for pneumonia.16
Active smoking was associated with changes in inflamma-
tory markers including lower FENO values, elevated blood 
leukocyte and neutrophil densities, and sputum neutrophil 
proportions. The ICS/SM group had a significantly higher 
blood neutrophil density compared with the ICS/NSM group. 
Inhaled corticosteroid use was associated with increased spu-
tum neutrophils and elevated CRP.
Severity definitions based on post-BD FEV1 predictably 
resulted in significant correlations to most spirometric param-
eters but provided an opportunity to evaluate how the global 
initiative in chronic obstructive lung disease (GOLD [Global 
Initiative for Chronic Obstructive Lung Disease]) severity1 
drove differences in other demographic, clinical characteristics 
and biomarkers. Only a few parameters, including RV/TLC 
(air trapping), and sputum neutrophils and macrophages segre-
gated by severity. Thus, post-BD FEV1 was associated with 
increased neutrophilic inflammation in sputum. Although the 
reasons for this are unclear, airflow obstruction progression 
may relate to a change and/or increase in lower airway micro-
biota, caused by reduced airway clearance, which may link to 
the increased risk of exacerbation. In a meta-analysis, Franciosi 
et  al17 also reported a rise in sputum neutrophils, as well as 
sputum interleukin 8 and serum CRP with COPD severity. 
However, in this study, serum CRP was associated with smok-
ing and ICS use but not with airway obstruction per se.
The prevalence of eosinophilic sputum inflammation was 
low in the COPD cohorts (13% of patients at cutoffs of 3% 
and 2%). These prevalences are lower than others have 
reported18,19 and this is topical in light of the recent interest in 
an asthma and COPD overlap syndrome (ACOS) which is 
characterized by BDR and also type 2 inflammation (eosino-
philia and elevated FENO).20 In a report by Alshabanat et al,21 
ACOS comprised 27% to 28% of the COPD population, 
whereas in that of Barrecheguren et al,22 up to 20% of COPD 
had ACOS. However, while approximately 1/3 of the ADEPT 
cohort showed reversible airflow obstruction, only 3% had an 
elevated FENO (>35 ppb), 13% had sputum eosinophilic 
inflammation, or 9% had high blood eosinophils (>300 cells/
mm3). The proportion of COPD subjects with sputum eosino-
phils >3% was higher in a report from Zanini et  al19 (31%). 
Singh et al18 reported that 31% of COPD subjects had persis-
tent blood eosinophilia (≥2%), but in a small subset with 
repeated sputum measures, only a minority (n = 138, 4%) had 
persistent sputum eosinophils ≥2%. Pascoe et al23 and Pavord 
et al24 both reported a greater prevalence of COPD with ele-
vated blood eosinophils, which predicted the reduction in exac-
erbation frequency to ICS.
The number of subjects who had quality sputum samples 
available for analysis was approximately 2/3 for the screening 
and/or baseline visits despite considerable efforts to use experi-
enced research sites and to train sites and subjects. The sputum 
success rate at the multiple sites in ADEPT was understanda-
bly lower than that achievable in highly specialized single cen-
tres.25,26 Based on our results here, together with a similar 
sputum success rate in the ADEPT asthma study,6 it is unlikely 
that profiling COPD with sputum feasible in the routine clini-
cal setting.
Limitations of the ADEPT population are predominantly 
due to protocol-mandated restrictions. The healthy control 
cohort was significantly younger than the COPD subjects and 
this affected multiple biomarkers (data not shown). We set the 
lower limit for post-BD FEV1 at 45% predicted due to the 
invasive procedures, thus not including very severe subjects. For 
similar reasons, COPD subjects were also required to be free of 
recent exacerbations, to have no history of life-threatening 
COPD exacerbations or right heart failure, and BMI was lim-
ited to <32 kg/m2. For these reasons, the study population 
included only a minority of subjects with frequent exacerba-
tions. When subsetting by active smoking and/or ICS use, 
which drove more differences in parameters than FEV1, the 
sample sizes are small. Unlike other programs, we did not 
include imaging, which would undoubtedly have added an 
important dimension to understanding phenotypes. Subjects 
were not followed up for a longer period as this was deemed to 
be too high a burden on these elderly symptomatic subjects. 
One gap, in light of the recent interest in the role of the micro-
biome,27 is the lack of microbial sampling. Finally, in retrospect 
and due to the profound impact of active smoking and ICS 
use, the study was relatively underpowered for analysis of 
high-dimensional biomarker data sets (eg, gene expression 
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microarray, proteomics), limiting such future analyses to 
exploratory, hypothesis-generating results.
Conclusions
In summary, ADEPT recruited a COPD cohort that under-
went extensive profiling with comparison with smoking and 
nonsmoking healthy controls. We report that active smoking 
status and ICS use were more impactful than severity based on 
post-BD FEV1 in determining clinical characteristics and bio-
markers. Studies that profile COPD should take into account 
ICS use and smoking status, in addition to severity of airflow 
obstruction when assessing phenotypes and endotypes.
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